Drug Profile
Research programme: anti-CD63 antibodies - Genentech
Alternative Names: AR1A245.6; AR7BD-33-11A; ARH460-22-1; CD63 programme - ARIUS/GenentechLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ARIUS Research
- Developer Genentech
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Lysosomal protein GP53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 24 Sep 2008 ARIUS Research has been acquired by Roche
- 20 Mar 2008 Preclinical development is ongoing